RICHMOND, Va., January 14, 2026 – Phlow Corp., a leading American pharmaceutical contract development and manufacturing organization (CDMO), today announced a major advancement in AI-driven Active Pharmaceutical Ingredient (API) manufacturing process development in...
Press Releases
Phlow Corp. CEO Outlines Path to Pharmaceutical Sovereignty in Testimony Before U.S. Senate
RICHMOND, Va., November 20, 2025 – Phlow Corp., a leading American pharmaceutical contract development and manufacturing organization (CDMO), announced today that its Co-Founder and Chief Executive Officer, Dr. Eric S. Edwards, M.D., Ph.D., testified before the United...
Phlow Corp. Congratulates the Commonwealth of Virginia and the Virginia Innovation Partnership Corporation on a Historic Investment to Create the Nation’s Largest Workforce Development Center for Advanced Pharmaceutical Manufacturing
RICHMOND, Va., November 3, 2025 – Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), congratulates Governor Glenn Youngkin, the Virginia Innovation Partnership Corporation (VIPC), and several leading...
Phlow Corp. Selected by the U.S. Food and Drug Administration Commissioner’s First-Ever National Priority Voucher Pilot Program to Advance Manufacturing of a Critical Essential Medicine in America
RICHMOND, Va., October 16, 2025 – Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that the active pharmaceutical ingredient for ketamine will be included in the first-ever U.S. Food...
Phlow Appoints Tim M. Mayleben as Chairman of the Board, Building on Bold Leadership and Expanding America’s Medicine Manufacturing Future
RICHMOND, Va, Oct. 15, 2025 — Phlow Corp., a leading American pharmaceutical contract development and manufacturing organization (CDMO), today announced that current board member and former advisory board member Tim M. Mayleben has been appointed Chairman of the Board...
Phlow Corp. and Antheia Partner to Bolster U.S. Pharmaceutical Supply Chains with Advanced Manufacturing Technologies
RICHMOND, Va., and MENLO PARK, Calif., July 29, 2025 – Phlow Corp., a leading American pharmaceutical contract development and manufacturing organization (CDMO) and Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains,...
Phlow Announces Close of $37M Series C Financing to Accelerate Modern Medicine Development and Manufacturing in America
Richmond, VA., July 22, 2025 – Phlow Corp., a leading American pharmaceutical contract development and manufacturing organization (CDMO), today announced the successful close of its Series C financing round at an increased valuation from previous funding....
Phlow Corp. Expands Analytical Capabilities and Embraces Artificial Intelligence-Driven System, Ushering in a New Era of Modern Medicine Manufacturing in America
Phlow Corp. Expands Analytical Capabilities and Embraces Artificial Intelligence-Driven System,Ushering in a New Era of Modern Medicine Manufacturing in America Richmond, Virginia — April 22, 2025 — Phlow Corp., a leading pharmaceutical contract development and...
Phlow Corp. Achieves Key Milestone Toward Full Epinephrine Production — Made in America
Validation Completed for a Novel, Cost-Competitive Epinephrine Active Pharmaceutical Ingredient Process, Drug Master File Successfully Filed Richmond, Virginia, March 17, 2025 -- Phlow Corp., a U.S.-based certified B Corporation on a mission to bring medicines to life...
Phlow Corp. Appoints General Gustave F. Perna to the Phlow Business Advisory Board
Richmond, VA., May 6, 2024 – Phlow Corp., a U.S.-based certified B Corporation leveraging advanced development and manufacturing processes to re-imagine the domestic production of pharmaceutical products critical to U.S. healthcare, announced today that it has...